iTeos to Present at Piper Sandler 32nd Annual Healthcare Conference
iTeos Therapeutics (Nasdaq: ITOS) announced participation in the Piper Sandler 32nd Annual Healthcare Conference from December 1-3, 2020. The fireside chat will be available on-demand for registered attendees. iTeos specializes in developing advanced immuno-oncology therapeutics, focusing on two clinical-stage programs: EOS-850, an adenosine A2a receptor antagonist, and EOS-448, targeting TIGIT. Both candidates are currently undergoing Phase 1/2a clinical trials for advanced solid tumors. For more details, visit their investor website.
- None.
- None.
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Nov. 23, 2020 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients, today announced that management will present at the Piper Sandler 32nd Annual Healthcare Conference, taking place December 1 – 3, 2020.
The fireside chat is now available for registered attendees to view on-demand through the duration of the event using the following link: https://pipersandler.zoom.us/rec/play/BpVKaQQBgtgH_2E-1VrjzcTFrYnR5C2p9oDagY_yXSEg1Uq7jJT7TazUadfvj3EGObsP6cX3aIuc7Y7M.VPHMhFu05uq-jZtF
A recording of the presentation is also available on the News and Events section of iTeos’ investor website at https://investors.iteostherapeutics.com/ and will remain active for 90 days.
About iTeos Therapeutics, Inc.
iTeos Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. iTeos Therapeutics leverages its deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. The innovative pipeline includes two clinical-stage programs targeting novel, validated immuno-oncology pathways designed to build on prior learnings in the field to have differentiated pharmacological and clinical profiles. The most advanced product candidate, EOS-850, is designed as a highly selective small molecule antagonist of the adenosine A2a receptor, in the adenosine triphosphate adenosine pathway, a key driver of immunosuppression in the tumor microenvironment across a broad range of tumors. EOS-850 is being investigated in an open-label Phase 1/2a clinical trial in adult patients with advanced solid tumors and encouraging preliminary single-agent activity were observed in the dose escalation portion of the trial. The lead antibody product candidate, EOS-448, is an antagonist of TIGIT, or T-cell immunoreceptor with Ig and ITIM domains, a checkpoint that has a role in both inhibitory and stimulatory pathways in the immune system. EOS-448 was also designed to engage the Fc gamma receptor, or FcγR, to promote antibody-dependent cellular cytotoxicity, or ADCC, activity, including the elimination of tumor-infiltrating regulatory T cells, or Tregs. An open-label Phase 1/2a clinical trial of EOS-448 was recently initiated in adult patients with advanced solid tumors. Therapeutics is headquartered in Cambridge, MA with a research center in Gosselies, Belgium.
For further information, please contact:
Investor Contacts:
Sarah McCabe, Zofia Mita
Stern Investor Relations, Inc.
+ 1 212 362 1200
iTeos@sternir.com
Media Contacts:
Amber Fennell, Paul Kidwell
Consilium Strategic Communications
+44 203 709 5700
iteos@consilium-comms.com
FAQ
When is iTeos Therapeutics presenting at the Piper Sandler Healthcare Conference?
What is the ticker symbol for iTeos Therapeutics?
Where can I watch the iTeos Therapeutics fireside chat?
What is EOS-850 developed by iTeos Therapeutics?
What is EOS-448 and its role in cancer treatment?
